Aktis Oncology, Inc (AKTS) Stock Price Today & Analysis

AKTS
AKTS company logo
Loading...
Chart by TradingViewData delayed 15 minutes

Valuation

Market cap$1.12B
Price-to-sales ratioN/A
Price-to-book valueN/A
Price-earnings ratio-24.10
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A

Earnings Per Share

Earnings Per Share$-16.42

Income Statement

Average volume222,846
EBITDAN/A
1 year high (52w)$29.16
1 year low (52w)$16.80

Dividend

Dividend yield0.00%

Solvency

Debt-to-equity ratioN/A

About Aktis Oncology, Inc

The company is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that have demonstrated transformative survival outcomes and meaningful quality-of-life benefits through the delivery of radioisotopes to solid tumors. These leading products, which target prostate-specific membrane antigen (PSMA) or the somatostatin-2 receptor, are each approved for only a single tumor type, yet have achieved substantial commercial adoption and have become foundational pillars of modern cancer treatment. Despite these advances, the company believes that the radiopharmaceutical field remains in its early stages, with many emerging companies continuing to focus primarily on these same two biological targets. In contrast, the company sees a significant opportunity to expand the range of cancer patients who may benefit from targeted radiopharmaceuticals by developing next-generation technologies designed to broaden the spectrum of tumor targets for which a potent alpha-emitting radioisotope payload can be delivered safely and effectively.

FAQ

Buying Aktis Oncology, Inc (AKTS) stock is now easy and instant through the Gotrade app.
  1. Download the Gotrade app from the App Store or Google Play.
  2. Create an account and complete KYC.
  3. Make a deposit.
  4. Search for the code "AKTS", then tap "Trade".
  5. Tap the "Buy" button.
  6. Enter the amount you want to buy. You have two options:
    1. Buy AKTS by number of shares.
    2. Buy fractional shares in dollars, starting from $1.
  7. Swipe up to confirm your order—done!
On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Aktis Oncology, Inc from just $1. A small budget shouldn't stop you from building a US stock portfolio.
At the moment, Aktis Oncology, Inc (AKTS) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track AKTS's performance via the price chart in the Gotrade app.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).
You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.
Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.
There's no single perfect answer, but common approaches include:
  • Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
  • Review revenue and earnings growth.
  • Check margins and cash flow.
  • Evaluate business outlook and the company's position within its industry.
You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Related news

AppLogo

Buy saham AKTS
di Gotrade

AppLogo

Gotrade